NSD3-NUT fusion oncoprotein in NUT midline carcinoma: Implications for a novel oncogenic mechanism

Cancer Discovery

Volumn 4, Issue 8, 2014, Pages 929-941

  French, Christopher A ^a   Rahman, Shaila ^b   Walsh, Erica M ^a   Kühnle, Simone ^b   Grayson, Adlai R ^a   Lemieux, Madeleine E ^h   Grunfeld, Noam ^a   Rubin, Brian P ^c,d   Antonescu, Cristina R ^e   Zhang, Songlin ^f   Venkatramani, Rajkumar ^g   Dal Cin, Paola ^a   Howley, Peter M ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Laboratory Medicine Institute   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h Bioinfo   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; INVOLUCRIN; KI 67 ANTIGEN; NSD3 ONCOPROTEIN; NUT ONCOPROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BRD4 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; NUCLEAR PROTEIN; NUT PROTEIN, HUMAN; TRANSCRIPTION FACTOR; WHSC1L1 PROTEIN, HUMAN;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; NONVIRAL GENE DELIVERY SYSTEM; NUT MIDLINE CARCINOMA; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; DRUG EFFECTS; FEMALE; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ADOLESCENT; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; TRANSCRIPTION FACTORS;

EID: 84905484015     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0014     Document Type: Article

References (57)

1. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 2003;63:304-7.
2. French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 2008;27:2237-42.
3. Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Luer SC, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012;18:5773-9.
4. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
5. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012;150:673-84.
6. Grayson AR, Walsh EM, Cameron MJ, Godec J, Ashworth T, Ambrose JM, et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 2014;33:1736-42.
7. Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005;19:535-45.
8. Rahman S, Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW, et al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 2011;31:2641-52.
9. Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J 2010;29:2943-52.
10. Haack H, Johnson L A, Fry C J, Crosby K, Polakiewicz R D, Stelow EB, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 2009;33:984-91.
11. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, et al. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 2000;92:1355-7.
12. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Gonzalez A, Gazdar AF, et al. Cloned fusion product from a rare t(15;19) (q13.2;p13.1) inhibit S phase in vitro. J Med Genet 2005;42:558-64.
13. Rosati R, La Starza R, Veronese A, Aventin A, Schwienbacher C, Vallespi T, et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 2002;99:3857-60.
14. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007;9:804-12.
15. Toretsky JA, Jenson J, Sun CC, Eskenazi AE, Campbell A, Hunger SP, et al. Translocation (11;15;19): a highly specifi c chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. Am J Clin Oncol 2003;26:300-6.
16. Kees U R, Mulcahy M T, Willoughby M L. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). Am J Pediatr Hematol Oncol 1991;13:459-64.
17. Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 2011;71:2686-96.
18. Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, et al. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. Oncogene 2013;32:4664-74.
19. Engleson J, Soller M, Panagopoulos I, Dahlen A, Dictor M, Jerkeman M. Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy. BMC Cancer 2006;6:69.
20. Yan J, Diaz J, Jiao J, Wang R, You J. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma. J Biol Chem 2011;286:27663-75.
21. Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Ann Rev Pathol 2012;7:283-301.
22. Ball A, Bromley A, Glaze S, French CA, Ghatage P, Kobel M. A rare case of NUT midline carcinoma. Gynecol Oncol Case Rep 2012;3:1-3.
23. Mills AF, Lanfranchi M, Wein RO, Mukand-Cerro I, Pilichowska M, Cowan J, et al. NUT midline carcinoma: a case report with a novel translocation and review of the literature. Head Neck Pathol 2014;8: 182-6.
24. Winkler K. Surgical treatment of pulmonary metastases in childhood. Thorac Cardiovasc Surg. 1986;34 Spec No 2:133-6.
25. Li Y, Trojer P, Xu CF, Cheung P, Kuo A, Drury WJ III, et al. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem 2009;284:34283-95.
26. Fang R, Barbera AJ, Xu Y, Rutenberg M, Leonor T, Bi Q, et al. Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. Mol Cell 2010;39:222-33.
27. Costanzi C, Pehrson JR. Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals. Nature 1998;393:599-601.
28. Gamble M J, Frizzell KM, Yang C, Krishnakumar R, Kraus WL. The histone variant macroH2A1 marks repressed autosomal chromatin, but protects a subset of its target genes from silencing. Genes Dev 2010;24:21-32.
29. Buschbeck M, Uribesalgo I, Wibowo I, Rue P, Martin D, Gutierrez A, et al. The histone variant macroH2A is an epigenetic regulator of key developmental genes. Nat Struct Mol Biol 2009;16:1074-9.
30. Novikov L, Park JW, Chen H, Klerman H, Jalloh AS, Gamble MJ. QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation. Mol Cell Biol 2011;31: 4244-55.
31. Sporn JC, Jung B. Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer. Am J Pathol 2012;180: 2516-26.
32. Creppe C, Janich P, Cantarino N, Noguera M, Valero V, Musulen E, et al. MacroH2A1 regulates the balance between self-renewal and differentiation commitment in embryonic and adult stem cells. Mol Cell Biol 2012;32:1442-52.
33. Morishita M, di Luccio E. Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta 2011;1816:158-63.
34. Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, Sirulnik A, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008;111: 3145-54.
35. Stec I, Wright TJ, van Ommen GJ, de Boer PA, van Haeringen A, Moorman AF, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 1998;7:1071-82.
36. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl W M, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025-34.
37. Garcia MJ, Pole JC, Chin SF, Teschendorff A, Naderi A, Ozdag H, et al. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 2005;24:5235-45.
38. Angrand P O, Apiou F, Stewart A F, Dutrillaux B, Losson R, Chambon P. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 2001;74:79-88.
39. Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res 2010;70:8487-97.
40. Zhou Z, Thomsen R, Kahns S, Nielsen AL. The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells. Biochem Biophys Res Commun 2010;398:565-70.
41. Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, et al. Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2012;109:5934-41.
42. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108:16669-74.
43. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
44. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8.
45. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011;21:381-95.
46. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36.
47. Best JD, Carey N. Epigenetic opportunities and challenges in cancer. Drug Discov Today 2010;15:65-70.
48. Marino-Enriquez A, Hornick JL, Dal Cin P, Cibas ES, Qian X. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fineneedle aspiration. Cancer Cytopathol 2014;122:128-37.
49. La Starza R, Barba G, Nofrini V, Pierini T, Pierini V, Marcomigni L, et al. Multiple EWSR1-WT1 and WT1-EWSR1 copies in two cases of desmoplastic round cell tumor. Cancer Genet 2013;206:387-92.
50. Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 2011;12:R72.
51. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009;25:1105-11.
52. Murphy GJ, Mostoslavsky G, Kotton DN, Mulligan RC. Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med 2006;12:1093-9.
53. Ince T A, Richardson A L, Bell G W, Saitoh M, Godar S, Karnoub AE, et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007;12:160-70.
54. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991;88:5523-7.
55. Henikoff S, Ahmad K, Platero JS, van Steensel B. Heterochromatic deposition of centromeric histone H3-like proteins. Proc Natl Acad Sci U S A 2000;97:716-21.
56. Senapedis WT, Kennedy CJ, Boyle PM, Silver PA. Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. Mol Biol Cell 2011;22:1791-805.
57. Stelow EB, French CA. Carcinomas of the upper aerodigestive tract with rearrangement of the nuclear protein of the testis (NUT) gene (NUT midline carcinomas). Adv Anat Pathol 2009;16:92-6.